Admitted to the Paris Bar in 2007, counsel Théophile Strebelle specialises in capital markets. He acts on a wide range of capital markets transactions, on equity securities (initial public offerings, share capital increases, private placements) and equity-linked securities, as well as on debt securities (Bonds, EMTNs, covered bonds, mortgage bonds, restructuring and buy-backs), including on innovative deals (Euro PP and crowdfunding).
Théophile was seconded to our New York office in 2016-2017 to work with French companies investing in the U.S. capital markets.
Théophile holds a postgraduate degree (Master 2) in Litigation Law (2006) and a Master’s degree in Private Law (2005), both from Paris II – Panthéon-Assas University.
« Gide Loyrette Nouel A.A.R.P.I. has a core focus on French issuer IPOs, but also has in-depth knowledge of US instruments, including Nasdaq listings, Regulation S and 144A transactions. Arnaud Duhamel is the key adviser and cross-border specialist Melinda Stege Arsouze is particularly active in private placements in the US. Counsels Théophile Strebelle and Guilhem Richard provide significant support. Recent work includes acting for Lysogène and Société Générale on Lysogène’s IPO on compartment C of Euronext Paris; advising BNP Paribas on a €143m capital increase for Société de la Tour Eiffel through preferential subscription rights; and handling Gensight Biologics’ private placement to investors in the US and Europe. The team has a strong following in the biotech sector, where clients also include Erytech Pharma and Inventiva. Goldman Sachs, Jefferies and Veolia are also clients. »
Legal 500 EMEA 2018